Trial Profile
Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 Attached to TCRζ and 4-1BB Signaling Domains in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Nov 2022
Price :
$35
*
At a glance
- Drugs CTL 119 (Primary) ; Tisagenlecleucel
- Indications Diffuse large B cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man
- 09 Nov 2022 Results (n=206) assessing the influence of household poverty and neighborhood social determinants on outcomes from CAR T-cell therapy for relapsed/refractory leukemia from (NCT01626495; NCT02435849 ; NCT02374333; NCT02228096; NCT02906371) clinical trials and commercial tisagenlecleucel from 2012 to 2020, published in the Blood.
- 07 Jun 2022 Results assessing impact of socioeconomic status on survival after CD19 CART therapy using data from CD19 CART clinical trials (NCT01626495, NCT02435849, NCT02374333, NCT02228096, NCT02906371) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition